These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31462289)

  • 1. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
    de Souza RP; Ribeiro ALR; de Menezes SAF; Machado LFA
    BMC Pediatr; 2019 Aug; 19(1):299. PubMed ID: 31462289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
    Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
    Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
    Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
    J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
    Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
    Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.
    Lekic E; Dragas L; Nikcevic D; Lekic J; Dedic A; Sulovic L
    Turk J Pediatr; 2024 May; 66(2):161-170. PubMed ID: 38814297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
    Castillo LM; Bugarin G; Arias JC; Barajas Rangel JI; Serra ME; Vain N
    J Pediatr (Rio J); 2017; 93(5):467-474. PubMed ID: 28236418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
    Ginsberg GM; Somekh E; Schlesinger Y
    Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab.
    Resch B; Michel-Behnke I
    Curr Opin Cardiol; 2013 Mar; 28(2):85-91. PubMed ID: 23337892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.